This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
5. The Pfizer CDK2/4/6 inhibitor PF-60873600 is orally bioavailable with Ki values of 0.09 nM, 1.3 nM, and 0.16 nM…
molecule
2 years ago ●
1 min read
6. The Lilly beta-site APP cleaving enzyme (BACE) inhibitor LY3202626 is an oral, low-dose, CNS-penetrant molecule which entered a Phase…
molecule
2 years ago ●
1 min read
7. The AstraZeneca inhaled dual PI3K_,_ inhibitor AZD8154 is long-acting in the lung but has low systemic exposure and is…
molecule
2 years ago ●
1 min read
8. The Gilead Toll-like receptor 7 (TLR7) agonist, vesatolimod (GS-9620), is a tolerated, low-dose oral TLR7 agonist. It is intended…
molecule
2 years ago ●
1 min read
9. The University of Michigan menin-MLL inhibitor, M-1121, is a covalent protein-protein interaction inhibitor that is orally active and achieves…
molecule
2 years ago ●
1 min read
10. The Chiesi M3 antagonist/PDE4 inhibitor dual pharmacology molecule, compound 92a, is an inhaled compound intended for pulmonary diseases. Both…
molecule
2 years ago ●
1 min read
Load More
